|Bid||115.00 x 1300|
|Ask||120.00 x 800|
|Day's range||115.70 - 117.65|
|52-week range||66.41 - 117.65|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||53.20|
|Earnings date||03 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||134.75|
DUBLIN, October 22, 2021--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named to Newsweek’s inaugural Most Loved Workplaces list for 2021, ranking among the top 100 companies recognized for employee happiness and satisfaction at work. Out of the companies recognized in the biotechnology and pharmaceutical category, Horizon ranked No. 1.
DUBLIN, October 21, 2021--Horizon Therapeutics announced data supporting the long-term efficacy of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
DUBLIN, October 13, 2021--Horizon Therapeutics announced results from a new analysis of UPLIZNA® (inebilizumab-cdon) in neuromyelitis optica spectrum disorder (NMOSD).